Published in Hepatitis Weekly, February 24th, 2003
"We have reported previously several cytotoxic T lymphocyte (CTL) epitopes derived from the HBV X antigen (HBx)," said Eunyoung Chun, Mogam Biotechnology Research Institute, South Korea. "In this study, we evaluated whether HBx-specific CTLs can be effectively used in adoptive cancer immunotherapy."
Researchers elected to test two HBx epitopes known to induce CTLs in humans for their study of adoptive immunotherapy. They used those epitopes, HBx 52-60(HLSLRGLFV)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.